INVESTORS

Upon technology transfer from the US to Germany in 2007, Rodos Biotarget was founded in 2008 receiving seed financing from High-Tech Gründerfonds and the Hannover innovation fund. In the following series A and series B rounds, the ERP Startfund of KfW and Hannover Beteiligungsfonds joint together with so far three family offices.

In 2016, Rodos Biotarget was among the first therapy-developing companies that raised funds from emerging crowdfunding platforms and the first Life Science company that employed in independent campaigns at two different platforms, namely Seedmatch and Ascuvest. 

Rodos has been involved in a number of consortia supported by national development banks and funding institutions:

Development of new antiviral and antitumoral therapy strategies using the cell-specific TargoSphere system.

Development of a new formulation for cell-specific antibiotic therapy at the example of Mycobacterium tuberculosis.

Development of new targeting anchors for targeted pharmacotherapy


TargoVir®: Production and verification of a highly innovative broad-spectrum virostatic in animal models

ANTI-TB – Antibiotic nanocarriers for therapeutic inhalation against tuberculosis

Development of a nanomedicine preparation for targeted treatment of chronic inflammatory autoimmune diseases

Rodos has been involved in a number of consortia supported by national development banks and funding institutions:

Development of new antiviral and antitumoral therapy strategies using the cell-specific TargoSphere system.

Development of a new formulation for cell-specific antibiotic therapy at the example of Mycobacterium tuberculosis.

TargoVir®: Production and verification of a highly innovative broad-spectrum virostatic in animal models

ANTI-TB – Antibiotic nanocarriers for therapeutic inhalation against tuberculosis


Development of new targeting anchors for targeted pharmacotherapy

Development of a nanomedicine preparation for targeted treatment of chronic inflammatory autoimmune diseases

GET IN TOUCH

Rodos BioTarget GmbH

Medical Park Hannover

Feodor-Lynen-Str. 31
30625 Hannover / Germany

Telefon: +49 (511) 7273 8835
Telefax: +49 (511) 7273 8837

E-Mail: info@biotargeting.eu
www.biotargeting.eu

Potsdam Science Park

Am Mühlenberg 11
14476 Potsdam / Germany

Telefon: +49 (511) 7273 8835
Telefax: +49 (511) 7273 8837

E-Mail: info@biotargeting.eu
www.biotargeting.eu